หน้าแรก เว็บบอร์ด หาเพื่อน Chat หาเพื่อน Line หาเพื่อน Skype โปรโมชั่น Pic Post ตรวจหวย ควิซ Page คำนวณ คำคม วิดีโอ สเปซ เกม Play ไดอารี่ อัลบั้ม แต่งรูป Glitter
 
ติดต่อเว็บไซต์ลงโฆษณาแจ้งเนื้อหาไม่เหมาะสมเงื่อนไขการให้บริการ
 
Login เข้าสู่ระบบ สมัครสมาชิก
 
ตรวจหวย งวดวันที่ 17 มกราคม 2563 สามตัว 379, 595
A non-invasive urine test for bladder cancer has been developed
14:48 - 12 มกราคม 2563

Researchers have developed a non-invasive urine test for bladder cancer.

The research background

A prospective double-blind study involving 577 hematuria patients demonstrated that a new noninvasive test for bladder cancer is 95% sensitive to high-risk cancers, with a negative predictive value greater than 97%. Researchers found that 7.96% (46) of patients had bladder cancer, while 92.1% (531) did not.

At the 37th Congress of the International Urological Association (SIU) in Portugal-Lisbon, it was announced that the ADXBLADDER test is expected to make non-invasive bladder cancer tests a reality. "Our study shows that ADXBLADDER has the highest sensitivity and negative predictive value of all bladder cancer urine tests," Stuart McCracken said at the SIU seminar.

“The new test method”, he added, “has some innovative features, including its susceptibility to urinary tract infections (UTIs), inflammation and hematuria”.

It is also very easy to use for enzyme-linked immunosorbent assay (ELISA) technology that has been promoted in many hospitals. This test requires only a 10ml urine sample and provides a clear “yes / no” result within 3 hours.

Current diagnostic techniques for bladder cancer

Bladder cancer is the fourth most common cancer in men in Europe and one of the most common cancers in women. A total of 151,000 people were diagnosed with this type of cancer in 2012.

In order to give accurate results for bladder cancer, the European Society of Urology recommends cystoscopy for all patients with hematuria, combined with CT urography (optionally used in high-risk patients) or ultrasound of the kidney and bladder.

Right now, cystoscopy cannot be replaced by cytology or any other non-invasive test. Most diagnostic methods of bladder cancer have shortcomings; cystoscopy is an invasive test. Patients often feel uncomfortable during the test and they are also exposed to the risk of urinary tract infections. The incidence of urinary tract infections after cystoscopy is known to be 5%. Therefore, the miss rate of cystoscopy can reach 30%.

The sensitivity of cytology is low, and urography exposes patients to ionizing radiation.

How does the non-invasive urine test work?

From August 2016 to February 2017, a total of 577 hematuria patients underwent ADXBLADDER and the results were compared with current diagnostic criteria for combined cystoscopy, ultrasound, and CT scans.

ADXBLADDER detects the level of cell proliferation markers (MCM5) by standard ELISA methods.

Urine samples from healthy bladder will not contain MCM5. Therefore, all cancer cells capable of dividing contain MCM5. When there is a tumor in the bladder, these cells that come into contact with the bladder and enter the urinary system will contain MCM5 markers.

The future of ADXBLADDER

ADXBLADDER is only 50% sensitive to low-risk bladder cancer, but researchers are not worried about it.

"Importantly," said McCracken from the University of Newcastle and Royal Sunderland Hospital. "ADXBLADDER has achieved very good sensitivity in high-risk patients and those who have had myometrial infiltration. These cancers spread rapidly. The prognosis is also very unsatisfactory. "

At the seminar, Tim Dudderidge, a surgeon from the University of Southampton Hospital, is considering how to integrate ADXBLADDER with current diagnostic methods.

For low-risk patients with no visible hematuria, he recommends using this method with ultrasound. The addition of the two results in 96.4% sensitivity.

For obvious high-risk patients, he emphasized that ultrasound and cystoscopy can be combined instead of CT scans. "I think this combination can be used to avoid unnecessary cystoscopy and CT scans based on the patient's risk," Dudderidge explained, and, for patients who do not meet the conditions for cystoscopy and CT scans, ADXBLADDER can be used as an independent inspection method. For example, those who have no visible hematuria under the age of 60 or who have had their hematuria resolved after treatment for a urinary tract infection.

It can also be used as a health screening method for high-risk groups, such as smokers and rubber or dye industry workers.

In order to improve human health globally, Creative Biolabs' mission is to provide extensive expertise in the development of valuable antibodies for diagnostic use to support our clients. With our versatile IVD platform, Creative Biolabs is proud to develop novel biomarker-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates). We are proud to share this expertise and our state-of-the-art facilities to facilitate their brilliant studies. Moreover, every project can be customized to meet your specific needs.

Potential biomarkers for bladder cancer development include but are not limited to:

EGF

Resistin

Retinoic acid-induced protein 3

Coronin-1A

DJ-1/PARK7

Chromosome 7

Chromosome 9p21

Apolipoprotein A1

α subunit of Gs

Gamma synuclein

Semenogelin-2

Fibrinogen

Apolipoprotein A4

Chromosome 3

Nuclear matrix protein 22

CFH

BLCA-4

CK8

Profilin 1

 
คอมเม้นต์
กรุณา "เข้าสู่ระบบ" ก่อนคอมเม้นต์
ผู้เขียน
บล็อกโปรด